Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Revenue - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt issuances

Cartesian Therapeutics (RNAC) Long-Term Debt Repayments (2017 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $24.9 million as the latest value for Q3 2023.

For Q3 2023, Long-Term Debt Repayments changed N/A year-over-year to $24.9 million; the TTM value through Dec 2024 reached $24.9 million, changed 0.0%, while the annual FY2023 figure was $27.5 million, N/A changed from the prior year.
Long-Term Debt Repayments hit $24.9 million in Q3 2023 for Cartesian Therapeutics, up from $15.1 million in the prior quarter.
Across five years, Long-Term Debt Repayments topped out at $24.9 million in Q3 2023 and bottomed at $700000.0 in Q3 2019.
Average Long-Term Debt Repayments over 3 years is $7.8 million, with a median of $2.1 million recorded in 2019.
On a YoY basis, Long-Term Debt Repayments climbed as much as 2059.0% in 2020 and fell as far as 2059.0% in 2020.
Cartesian Therapeutics' Long-Term Debt Repayments stood at $2.1 million in 2019, then skyrocketed by 619.67% to $15.1 million in 2020, then surged by 64.57% to $24.9 million in 2023.
According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $24.9 million, $15.1 million, and $2.1 million for Q3 2023, Q3 2020, and Q2 2020 respectively.